LUMEN TECHNOLOGIES INC (1CYTH.MI) Stock Fundamental Analysis
BIT:1CYTH - Euronext Milan - US5502411037 - Common Stock - Currency: EUR
We assign a fundamental rating of 2 out of 10 to 1CYTH. 1CYTH was compared to 31 industry peers in the Diversified Telecommunication Services industry. 1CYTH has a bad profitability rating. Also its financial health evaluation is rather negative. 1CYTH has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
1CYTH had negative earnings in the past year.
1CYTH had a positive operating cash flow in the past year.
1CYTH had negative earnings in 4 of the past 5 years.
1CYTH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
1CYTH's Return On Assets of -0.93% is on the low side compared to the rest of the industry. 1CYTH is outperformed by 67.74% of its industry peers.
1CYTH's Return On Equity of -108.30% is on the low side compared to the rest of the industry. 1CYTH is outperformed by 83.87% of its industry peers.
The Return On Invested Capital of 1CYTH (1.29%) is worse than 77.42% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for 1CYTH is below the industry average of 7.13%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.93% | ||
| ROE | -108.3% | ||
| ROIC | 1.29% |
ROA(3y)-11.28%
ROA(5y)-6.48%
ROE(3y)-832.11%
ROE(5y)-498.04%
ROIC(3y)3.43%
ROIC(5y)4.35%
1.3 Margins
1CYTH's Operating Margin of 3.98% is on the low side compared to the rest of the industry. 1CYTH is outperformed by 70.97% of its industry peers.
In the last couple of years the Operating Margin of 1CYTH has declined.
1CYTH's Gross Margin of 48.17% is on the low side compared to the rest of the industry. 1CYTH is outperformed by 67.74% of its industry peers.
In the last couple of years the Gross Margin of 1CYTH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.98% | ||
| PM (TTM) | N/A | ||
| GM | 48.17% |
OM growth 3Y-44.91%
OM growth 5Y-27.05%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.94%
GM growth 5Y-3.18%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), 1CYTH is destroying value.
The number of shares outstanding for 1CYTH has been increased compared to 1 year ago.
The number of shares outstanding for 1CYTH has been reduced compared to 5 years ago.
Compared to 1 year ago, 1CYTH has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.22, we must say that 1CYTH is in the distress zone and has some risk of bankruptcy.
1CYTH has a Altman-Z score of -0.22. This is amonst the worse of the industry: 1CYTH underperforms 80.65% of its industry peers.
1CYTH has a debt to FCF ratio of 17.37. This is a negative value and a sign of low solvency as 1CYTH would need 17.37 years to pay back of all of its debts.
1CYTH's Debt to FCF ratio of 17.37 is on the low side compared to the rest of the industry. 1CYTH is outperformed by 64.52% of its industry peers.
A Debt/Equity ratio of 59.98 is on the high side and indicates that 1CYTH has dependencies on debt financing.
With a Debt to Equity ratio value of 59.98, 1CYTH is not doing good in the industry: 83.87% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 59.98 | ||
| Debt/FCF | 17.37 | ||
| Altman-Z | -0.22 |
ROIC/WACC0.19
WACC6.73%
2.3 Liquidity
A Current Ratio of 1.21 indicates that 1CYTH should not have too much problems paying its short term obligations.
1CYTH has a Current ratio of 1.21. This is amongst the best in the industry. 1CYTH outperforms 87.10% of its industry peers.
1CYTH has a Quick Ratio of 1.17. This is a normal value and indicates that 1CYTH is financially healthy and should not expect problems in meeting its short term obligations.
1CYTH has a Quick ratio of 1.17. This is amongst the best in the industry. 1CYTH outperforms 90.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
1CYTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -700.00%.
The Revenue has decreased by -7.86% in the past year.
Measured over the past years, 1CYTH shows a decrease in Revenue. The Revenue has been decreasing by -9.39% on average per year.
EPS 1Y (TTM)-700%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-225%
Revenue 1Y (TTM)-7.86%
Revenue growth 3Y-12.68%
Revenue growth 5Y-9.39%
Sales Q2Q%-3.28%
3.2 Future
The Earnings Per Share is expected to grow by 6.48% on average over the next years.
The Revenue is expected to decrease by -1.83% on average over the next years.
EPS Next Y-383.61%
EPS Next 2Y-97.25%
EPS Next 3Y-39.06%
EPS Next 5Y6.48%
Revenue Next Year-4.59%
Revenue Next 2Y-4.03%
Revenue Next 3Y-3.28%
Revenue Next 5Y-1.83%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for 1CYTH. In the last year negative earnings were reported.
Also next year 1CYTH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1CYTH is valued a bit cheaper than 64.52% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 1CYTH is valued cheaply inside the industry as 96.77% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.16 | ||
| EV/EBITDA | 5.81 |
4.3 Compensation for Growth
A cheap valuation may be justified as 1CYTH's earnings are expected to decrease with -39.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-97.25%
EPS Next 3Y-39.06%
5. Dividend
5.1 Amount
1CYTH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1CYTH (6/12/2025, 7:00:00 PM)
3.565
-0.16 (-4.22%)
Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupTelecommunication Services
GICS IndustryDiversified Telecommunication Services
Earnings (Last)
Earnings (Next)
Inst Owners70.4%
Inst Owner ChangeN/A
Ins Owners7.48%
Ins Owner ChangeN/A
Market Cap3.65B
Analysts55.56
Price Target4.15 (16.41%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)-68.79%
DP-0.32%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)162.07%
Min EPS beat(2)52.11%
Max EPS beat(2)272.03%
EPS beat(4)2
Avg EPS beat(4)40.12%
Min EPS beat(4)-118.13%
Max EPS beat(4)272.03%
EPS beat(8)4
Avg EPS beat(8)-60.86%
EPS beat(12)6
Avg EPS beat(12)-32.44%
EPS beat(16)9
Avg EPS beat(16)-19.77%
Revenue beat(2)1
Avg Revenue beat(2)0.93%
Min Revenue beat(2)-0.09%
Max Revenue beat(2)1.96%
Revenue beat(4)1
Avg Revenue beat(4)-0.32%
Min Revenue beat(4)-1.86%
Max Revenue beat(4)1.96%
Revenue beat(8)1
Avg Revenue beat(8)-1.09%
Revenue beat(12)1
Avg Revenue beat(12)-1.28%
Revenue beat(16)1
Avg Revenue beat(16)-1.56%
PT rev (1m)-22.81%
PT rev (3m)-22.81%
EPS NQ rev (1m)-57.39%
EPS NQ rev (3m)-57.39%
EPS NY rev (1m)-48.7%
EPS NY rev (3m)-48.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)0.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.33 | ||
| P/FCF | 4.16 | ||
| P/OCF | 0.98 | ||
| P/B | 14.63 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.81 |
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)0.86
FCFY24.06%
OCF(TTM)3.65
OCFY102.33%
SpS10.96
BVpS0.24
TBVpS-5.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.93% | ||
| ROE | -108.3% | ||
| ROCE | 1.72% | ||
| ROIC | 1.29% | ||
| ROICexc | 1.38% | ||
| ROICexgc | 1.81% | ||
| OM | 3.98% | ||
| PM (TTM) | N/A | ||
| GM | 48.17% | ||
| FCFM | 7.82% |
ROA(3y)-11.28%
ROA(5y)-6.48%
ROE(3y)-832.11%
ROE(5y)-498.04%
ROIC(3y)3.43%
ROIC(5y)4.35%
ROICexc(3y)3.6%
ROICexc(5y)4.47%
ROICexgc(3y)6.03%
ROICexgc(5y)8.09%
ROCE(3y)4.57%
ROCE(5y)5.8%
ROICexcg growth 3Y-47.53%
ROICexcg growth 5Y-31.85%
ROICexc growth 3Y-41.43%
ROICexc growth 5Y-24.11%
OM growth 3Y-44.91%
OM growth 5Y-27.05%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.94%
GM growth 5Y-3.18%
F-Score5
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 59.98 | ||
| Debt/FCF | 17.37 | ||
| Debt/EBITDA | 5.04 | ||
| Cap/Depr | 113.28% | ||
| Cap/Sales | 25.45% | ||
| Interest Coverage | 0.44 | ||
| Cash Conversion | 125.83% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | -0.22 |
F-Score5
WACC6.73%
ROIC/WACC0.19
Cap/Depr(3y)102.09%
Cap/Depr(5y)91.52%
Cap/Sales(3y)21.07%
Cap/Sales(5y)19.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-700%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-225%
EPS Next Y-383.61%
EPS Next 2Y-97.25%
EPS Next 3Y-39.06%
EPS Next 5Y6.48%
Revenue 1Y (TTM)-7.86%
Revenue growth 3Y-12.68%
Revenue growth 5Y-9.39%
Sales Q2Q%-3.28%
Revenue Next Year-4.59%
Revenue Next 2Y-4.03%
Revenue Next 3Y-3.28%
Revenue Next 5Y-1.83%
EBIT growth 1Y-37.71%
EBIT growth 3Y-51.9%
EBIT growth 5Y-33.9%
EBIT Next Year401.19%
EBIT Next 3Y75.48%
EBIT Next 5Y43.46%
FCF growth 1Y16.1%
FCF growth 3Y-32.61%
FCF growth 5Y-18.43%
OCF growth 1Y9.38%
OCF growth 3Y-12.65%
OCF growth 5Y-8.29%